SCHEMBL7086468

SCHEMBL7086468

O=C(O)NS(=O)(=O)Nc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
IL1RN P18510 1/20 0.48
ERAP1 Q9NZ08 1/20 0.48
ACP1 P24666 2/20 0.47
CA12 O43570 2/20 0.46
CA9 Q16790 2/20 0.46
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 1/20 0.45
PKM P14618 1/20 0.45
TP53 P04637 1/20 0.43
EPHX1 P07099 1/20 0.43
TSHR P16473 1/20 0.43
EPHX2 P34913 1/20 0.43
CDK9 P50750 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
HDAC3 O15379 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3053462 0.83 HDAC2 (0.54) KEAP1CA1CA2CA12CA9
SCHEMBL3802959 0.83 CA1 (0.52) KEAP1CA1CA2IL1RNERAP1
SCHEMBL19971753 0.82 ACP1 (0.67) CA1CA2ACP1CA12CA9
SCHEMBL3204466 0.82 POLB (0.52) CA1CA2CA12CA9KMT2A
SCHEMBL59151 0.81 KEAP1 (0.64) KEAP1CA1CA2IL1RNERAP1
SCHEMBL11583151 0.80 KEAP1 (0.44) KEAP1CA1CA2IL1RNERAP1
SCHEMBL14409297 0.79 TGM2 (0.56) KEAP1CA1CA2IL1RNERAP1
SCHEMBL9302939 0.79 KEAP1 (0.42) KEAP1CA1CA2IL1RNERAP1
SCHEMBL23141160 0.79 KEAP1 (0.61) KEAP1CA1CA2IL1RNERAP1
SCHEMBL27640456 0.78 TMPRSS6 (0.51) KEAP1CA1CA2IL1RNERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0592439-B1 AMINOSULFONYL CARBAMATES WARNER LAMBERT CO (US) 2003-07-30 EP claimed
EP-2970116-A1 ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS F. Hoffmann-La Roche AG (CH) 2016-01-20 EP disclosed
US-8912219-B2 Aryl sulfamide and sulfamate derivatives as RORc modulators GENENTECH, INC. (US) 2014-12-16 US disclosed
WO-2014140059-A1 ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2014-09-18 WO disclosed
US-20140275032-A1 ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS GENENTECH, INC. (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275032-A1 ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS RORA, RORC, RORB KEAP1 2586/4885CA1 2133/4885CA2 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.